Brigham and Women's Hospital
Fellowship
University of Bern
Fellowship
Beth Israel Deaconess Medical Center
Residency
Beth Israel Deaconess Medical Center
Internship
Harvard Medical School
MD
Preparing surgeons for advocacy: A framework for trainees.
Preparing surgeons for advocacy: A framework for trainees. Surgery. 2025 Dec; 188:109675.
PMID: 40961725
Surgical advocacy as an academic career path: A guide for promotion discussions.
Surgical advocacy as an academic career path: A guide for promotion discussions. Surgery. 2025 Nov; 187:109650.
PMID: 40929951
Validation of the uChicago Health Inequity Classification System (CHI-CS): A multi-institution pilot study.
Validation of the uChicago Health Inequity Classification System (CHI-CS): A multi-institution pilot study. Surgery. 2025 Sep; 185:109528.
PMID: 40570446
Surgeon as advocate: A widening lane.
Surgeon as advocate: A widening lane. Surgery. 2025 Sep; 185:109515.
PMID: 40561900
Training the Surgeon-Scientist: Time (and Money) Well Spent?
Training the Surgeon-Scientist: Time (and Money) Well Spent? Ann Surg. 2025 Dec 01; 282(6):906-907.
PMID: 40504070
Enhancing equity in academic surgery promotion practices.
Enhancing equity in academic surgery promotion practices. Surgery. 2025 04; 180:109023.
PMID: 39837048
A rendezvous approach for ampullary access in a strictured duodenojejunostomy.
A rendezvous approach for ampullary access in a strictured duodenojejunostomy. VideoGIE. 2025 May; 10(5):250-252.
PMID: 40255627
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
PMID: 39625569
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
PMID: 39277672
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
PMID: 39277671